الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 166 |  |  |
| | | from | 166 | | |
Abstract
”treatment for CLI was endovascular or surgical revascularization. However, so far, there was no effective pharmacotherapy for the treatment or prevention of CLI. In the present study, unilateral ligation and excision of femoral artery resulted in CLI features experimentally. Peripheral ischemia was confirmed by the elevation of HIF-1α and VEGF-A levels that coincided with enhanced CD34 expression in GC muscles. Ischemia resulted in decreased total antioxidant capacity and enhanced inflammatory signal that was confirmed by elevation of TNF-α and ERK1/2 levels. Moreover, ischemic limbs manifested significant apoptosis as detected by immune-fluorescence labelling of TUNEL that was accompanied by histopathological alterations and impaired motor function. In conclusion : Treatment with Rho-associated coiled-coil protein kinase (ROCK) inhibitor; Fasudil showed promising alleviation of peripheral ischemia experimentally. Mice treated with Fasudil experienced declined levels of HIF-1α and VEGF-A as well as normalization of CD34 expression in GC muscles, peripherally. It preserved antioxidant capacity and alleviated inflammation through reduction of TNF-α and ERK1/2 levels. In addition, it improved apoptosis/proliferation ratio in GC muscles that was accompanied by attenuated histopathological features and improved peripheral motor function. Yet, the overall outcomes of the current study support the protective potential of the ROCK inhibitor ; Fasudil in peripheral vascular diseases and contribute to paving the way for its clinical application for patients suffering ischemic vascular diseases.